Zhitong Finance App News, Federal Pharmaceutical (03933) issued an announcement. Sodium hyaluronate eye drops (specification: 0.3% (5ml: 15mg)) declared by the Zhongshan Branch of Zhuhai Federal Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the Company, have passed the drug registration approval by the China National Drug Administration. Drug approval number: Sinopharm Standard H20269162.

Sodium hyaluronate eye drops are artificial tears and are suitable for corneal conjunctival epithelial damage associated with endogenous diseases such as Sjogne syndrome, and dry eye syndrome; as well as external diseases such as post-surgery, drug, trauma, and contact lens wearing. The single dose specification for sodium hyaluronate eye drops already on the market is 0.3% (0.4 ml: 1.2 mg), and the new multi-dose specification approved is 0.3% (5 ml: 15 mg). Currently, sodium hyaluronate eye drops are Class B drugs in the National Medical Insurance Catalogue (2025 edition).

This approval will further expand the layout of federal pharmaceuticals' ophthalmology products and strengthen the company's competitiveness in the field of dry eye medication. In the future, the company will continue to work on new product research and development, and continue to enhance its competitiveness and creativity in the pharmaceutical industry, which is expected to generate greater benefits for the company and its shareholders.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.